Drug Profile

Research programme: oral glucagon-like peptide-1 receptor agonists - Novo Nordisk

Latest Information Update: 14 Dec 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novo Nordisk
Class Glucagon-like peptides; Small molecules
Mechanism of Action Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

No development reported Type 2 diabetes mellitus

Most Recent Events

08 Dec 2020 Emisphere Technologies has been acquired by Novo Nordisk
04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Denmark (PO)
30 Apr 2013 Oral glucagon-like peptide-1 receptor agonists are available for licensing as of 30 Apr 2013. http://www.novonordisk.com

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com